University of Cincinnati
11/07/2025 | Press release | Distributed by Public on 11/07/2025 08:55
Combination immunotherapy helps overcome melanoma treatment resistance
Combination immunotherapy helps overcome melanoma treatment resistance
Cancer Center researcher presents abstract at SITC Annual Meeting
By Tim Tedeschi Email TimEmail Tim 513-556-5694
3 minute read November 7, 2025 Share on facebook Share on Twitter Share on LinkedIn Share on Reddit Print StoryLike
Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
The University of Cincinnati Cancer Center's Trisha Wise-Draper, MD, PhD, will present a late-breaking abstract detailing the trial results at the Society for Immunotherapy of Cancer 40th Anniversary Annual Meeting Nov. 7.
Oncolytic viruses are specially engineered to infect and destroy cancer cells. The Phase 2 IGNYTE trial is testing RP1, a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate a robust antitumor immune response.
The trial is testing RP1 in combination with nivolumab, an immunotherapy drug that targets PD-1 protein receptors on tumors to help the body's own immune system identify and attack cancer cells.
Reviewing data from 140 patients enrolled in the trial, Wise-Draper and colleagues found the combination of RP1 and nivolumab led to increased immune response, immune cell infiltration and activation within tumors in patients who had not previously responded to immunotherapy, indicating RP1 helps overcome treatment resistance.
"The trial itself was positive in that approximately one-third of the patients with refractory melanoma will respond to this combination, and responses are durable," said Wise-Draper, professor of medicine in the Division of Hematology/Oncology, section head of medical oncology, co-leader of the Head and Neck Experimental Advancement Laboratory in UC's College of Medicine, and deputy director of UC's Office of Clinical Research. "This is a promising combination that is well tolerated for patients with PD1 refractory melanoma."
Impact Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact.
Other abstract coauthors include Praveen Bommareddy, Caroline Robert, Joseph J. Sacco, Gino K. In, Eva Muñoz Couselo, Dirk Schadendorf, Jiaxin Niu, Georgia M. Beasley, Bartosz Chmielowski, Mohammed M. Milhem, Tawnya Lynn Bowles, Katy K. Tsai, Céleste Lebbé, Caroline Gaudy-Marqueste, Adel Samson, Junhong Zhu, Marcus Viana, Chris Tucci, Bhavna Paratala, Jeannie W. Hou and Michael K. Wong.
Featured photo at top of Wise-Draper. Photo/Nyla Sauter/University of Cincinnati Cancer Center.
Tags
- Faculty Staff
- College of Medicine
- University of Cincinnati Cancer Center
- Academic Health Center
- Health
- Research
Related Stories
1
Cancer Center experts present at national conference
May 27, 2025
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology Annual Meeting May 30 to June 3 in Chicago.
2
New clinical trial aims to optimize pain management and reduce opioid use after mastectomy
March 7, 2025
MSN highlighted a new University of Cincinnati Cancer Center clinical trial aimed to optimize pain management and reduce the need for opioids after mastectomy procedures.
3
UC researchers working to make blood cancer a manageable illness
September 15, 2025
Researchers in the University of Cincinnati Cancer Center's Leukemia and Drug Development Lab are working to make blood cancer a manageable illness and bring new treatments to patients more efficiently than ever before.
University of Cincinnati published this content on November 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 07, 2025 at 14:55 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]